Γ

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Check this box if no longer subject to
L	Section 16. Form 4 or Form 5 obligations
1	may continue. See Instruction 1(b).

Check this box to indicate that a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

contract, instruct purchase or sale issuer that is inte	nade pursuant to a on or written plan for of equity securities o nded to satisfy the se conditions of Rule					
1. Name and Addre	ss of Reporting Pe	rson*	2. Issuer Name and Ticker or Trading Symbol LIXTE BIOTECHNOLOGY HOLDINGS, INC. [LIXT]		tionship of Reporting Pers all applicable) Director Officer (give title	on(s) to Issuer 10% Owner Other (specify
(Last) 680 E. COLOR	(First) ADO BLVD., S	(Middle) UITE 180	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2025		below)	below)
(Street) PASADENA (City)	CA (State)	91101 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing Form filed by One Rep Form filed by More tha	,
		Table I - Non	-Derivative Securities Acquired, Disposed of, or Benefici	ally Ow	ned	

2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct (D) 1. Title of Security (Instr. 3) 2A. Deemed 5. Amount of Securities 7. Nature of 3. Transaction Execution Date, Indirect (Month/Day/Year) if any Code (Instr. Beneficially Owned or Indirect (I) Beneficial (Month/Day/Year) Following Reported Transaction(s) Ownership (Instr. 4) 8) (Instr. 4) (A) or (D) v Price (Instr. 3 and 4) Code Amount

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)		ate	7. Title and An Securities Und Derivative Sec 3 and 4)	derlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Options to Purchase Common Stock	\$0.905	06/30/2025		A		10,000		09/30/2025	06/30/2030	Common	10,000	\$0 ⁽¹⁾	10,000	D	
Options to Purchase Common Stock	\$0.905	06/30/2025		A		11,632		06/30/2025	06/30/2030	Common	11,652	\$0 ⁽²⁾	11,632	D	
Options to Purchase Common Stock	\$1.21							03/31/2025	03/31/2030	Common	8,777		8,777	D	
Options to Purchase Common Stock	\$2.33							01/20/2025	01/20/2030	Common	4,545		4,545	D	
Options to Purchase Common Stock	\$1.3							09/30/2024	09/30/2029	Common	5,786		5,786	D	
Options to Purchase Common Stock	\$2.37							06/30/2024	06/30/2029	Common	10,000		10,000	D	
Options to Purchase Common Stock	\$2.37							06/30/2024	06/30/2029	Common	4,527		4,527	D	
Options to Purchase Common Stock	\$7.45							06/30/2022	06/30/2027	Common	10,000		10,000	D	
Options to Purchase Common Stock	\$30.3							06/30/2021	06/30/2026	Common	10,000		10,000	D	
Options to Purchase Common Stock	\$32.1							01/06/2021	01/06/2026	Common	5,000		5,000	D	
Warrants to Purchase Common Stock	\$57							11/30/2020	11/30/2025	Common	5,263		5,263	I	By Sino- American Cancer FDD
Options to Purchase Common Stock	\$16.8							08/04/2018	08/04/2023	Common	3,333		3,333	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Options to Purchase Common Stock	\$66						05/22/2019	05/22/2024	Common	833		833	D	

Explanation of Responses:

1. Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.

2. Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

<u>/s/ Yun Yen</u> ** Signature of Reporting Person 07/09/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.